Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Comparison Tests01:13

Multiple Comparison Tests

Multiple comparison test, abbreviated as MCT, is a post hoc analysis generally performed after comparing multiple samples with one or more tests. An MCT will help identify a significantly different sample among multiple samples or a factor among multiple factors.
It would be easy to compare two samples using a significance alpha level of 0.05. In other words, there is only one sample pair to be compared. However, it would be difficult to identify a significantly different sample if the number...
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
Drug Product Performance: In Vitro–In Vivo Correlation01:20

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while adhering...
In Vitro Drug Dissolution: Compendial Testing Models I01:13

In Vitro Drug Dissolution: Compendial Testing Models I

Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
In Vitro Drug Dissolution: Compendial Testing Models II01:09

In Vitro Drug Dissolution: Compendial Testing Models II

Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients, maintaining...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proposed Meropenem Breakpoints for Interpretation of Antimicrobial Susceptibility Testing of Bacteria Isolated From Dogs.

Journal of veterinary pharmacology and therapeutics·2026
Same author

A Top-Down Physiologically Based Pharmacokinetic Modeling Approach to Explore Unexpected Bio-inequivalence of Experimental Oral Formulations in Dogs.

Pharmaceutical research·2026
Same author

The Need for a Revision of Fluoroquinolone Breakpoints for Interpretation of Antimicrobial Susceptibility Testing of Feline Bacterial Isolates.

Journal of veterinary pharmacology and therapeutics·2025
Same author

A Bottom-up Approach for Mutant and Wild Type Collies Using Physiologically Based Pharmacokinetic (PBPK) Modeling: A Case Study Using Loperamide.

The AAPS journal·2025
Same author

Evolving value and validity of animal models in veterinary therapeutic research: Impact of scientific progress.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2025
Same author

Factoring fu Variability Into Estimates of Unbound Drug Concentrations Negatively Biases the MIC Versus % Probability of Target Attainment Relationship of Antimicrobial Agents.

Journal of veterinary pharmacology and therapeutics·2025

Related Experiment Video

Updated: Jun 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

Initial Exploration on the Application of the MoCMC Approach for Determining In Vitro Product Comparability.

Marilyn N Martinez1, David G Longstaff2

  • 1Office of Generic Animal Drugs, Center for Veterinary Medicine, US Food and Drug Administration, Department of Health and Human Services, College Park, Maryland, USA. marilyn.martinez@fda.hhs.gov.

Pharmaceutical Research
|June 26, 2026
PubMed
Summary

The Matrix of Chemistry, Manufacturing and Control (MoCMC) approach shows promise for assessing physicochemical similarity in non-systemically absorbed drugs. It can detect product differences missed by dissolution testing, aiding bioequivalence studies.

Keywords:
in vitro bioequivalenceMoCMClocally acting drug productveterinary medicine

More Related Videos

The Multi-organ Chip - A Microfluidic Platform for Long-term Multi-tissue Coculture
10:05

The Multi-organ Chip - A Microfluidic Platform for Long-term Multi-tissue Coculture

Published on: April 28, 2015

Related Experiment Videos

Last Updated: Jun 28, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

The Multi-organ Chip - A Microfluidic Platform for Long-term Multi-tissue Coculture
10:05

The Multi-organ Chip - A Microfluidic Platform for Long-term Multi-tissue Coculture

Published on: April 28, 2015

Area of Science:

  • Pharmaceutical Sciences
  • Drug Product Quality Assessment
  • Bioequivalence Studies

Background:

  • Evaluating physicochemical similarity is crucial for bioequivalence assessment, especially for non-systemically absorbed drugs.
  • Traditional methods like in vitro dissolution may not capture all relevant product differences.
  • The Matrix of Chemistry, Manufacturing and Control (MoCMC) approach offers a novel framework for Q3 similarity evaluation.

Purpose of the Study:

  • To conduct an initial assessment of the MoCMC approach for evaluating physicochemical (Q3) similarity.
  • To determine the utility of MoCMC in bioequivalence assessments for products with non-systemically absorbed drugs.

Main Methods:

  • Expressed Q3 parameters as polygon radii using a mathematical formula.
  • Calculated the Matrix Comparability Index (MCI) as the ratio of product area to outer area.
  • Statistically compared MCI values across multiple lots and used actual and hypothetical data for performance characterization.

Main Results:

  • The influence of individual Q3 parameters diminished with an increased number of radii.
  • Increased variability in MCI values reduced the ability to detect statistically significant product differences.
  • MoCMC, combined with statistical analysis, identified product differences not detected by dissolution profiles alone.

Conclusions:

  • The MoCMC approach is a viable tool for comparing products containing non-systemically absorbed drugs.
  • Statistical refinements are necessary for applying MoCMC in bioequivalence evaluations.
  • Further development of the MoCMC approach for bioequivalence is ongoing.